GNA15

GNA15 encodes a hematopoietic-restricted Gq-class G protein alpha subunit that transduces GPCR signals into proliferative and survival programs across normal hematopoietic and malignant cells (PMID:8838318, PMID:25701539). It arose by tandem duplication alongside Gna11 but, unlike the ubiquitously expressed Gna11, its expression is confined to hematopoietic lineages (PMID:8838318). Gα15 couples promiscuously to diverse GPCRs—including the β1 adrenergic receptor in neuroendocrine tumor cells, where its loss suppresses proliferation, triggers apoptosis, and dampens ERK, NFκB, and Akt signaling (PMID:25701539), and the adhesion GPCR CD312, which engages Gα15 at its transmembrane intracellular segment to drive leukemia cell proliferation via ERK, JNK, and p38 phosphorylation (PMID:39656442). In thyroid carcinoma, Gα15 binds BTK to activate the same MAPK cascade, with BTK acting as a required intermediate for malignant proliferation, migration, and invasion (PMID:38333922). Beyond canonical MAPK output, Gα15 reprograms metabolism in B-ALL leukemia cells by upregulating AMPK phosphorylation and the fatty acid oxidation machinery (CPT1, CPT2, CD36), conferring drug resistance reversible by FAO inhibition (PMID:39812998). Collectively these findings position Gα15 as a node linking GPCR engagement to MAPK-driven growth and metabolic adaptation in cancer.

1. 1996 Medium

   Established GNA15 as a distinct Gq-class alpha subunit gene whose expression—unlike its paralog Gna11—is restricted to hematopoietic cells, defining the lineage context for its later signaling roles.

   Evidence Genomic sequencing and gene-structure characterization with Northern blot tissue profiling in mouse

   PMID:8838318

   Open questions at the time

   • No biochemical demonstration of GPCR coupling or downstream effector at this stage
   • Functional role of the hematopoietic restriction untested
2. 2002 Low

   Raised the possibility of in vivo coupling between Gα15 and the S1P4/Edg6 receptor based on tandem genomic arrangement and co-expression, addressing which GPCRs Gα15 might serve.

   Evidence Genomic co-localization analysis and Northern blot expression correlation in mouse and human

   PMID:12401211

   Open questions at the time

   • Functional coupling between Gα15 and S1P4 proposed from co-expression only, not experimentally confirmed
   • No signaling readout
3. 2015 Medium

   Demonstrated direct functional GPCR coupling, showing Gα15 links the β1 adrenergic receptor to proliferative MAPK/NFκB/Akt signaling in neuroendocrine tumor cells.

   Evidence Reciprocal immunoprecipitation coupling assay plus siRNA knockdown with proliferation/apoptosis and pathway Western blots in KRJ-I cells

   PMID:25701539

   Open questions at the time

   • Single cell line context
   • Direct GTP-loading/effector activation by Gα15 not measured
   • Receptor specificity beyond β1AR not mapped
4. 2024 Medium

   Defined a BTK-dependent route from Gα15 to the full MAPK cascade (ERK/JNK/p38) driving malignant behavior, addressing how Gα15 transmits signal to the kinase module.

   Evidence Co-immunoprecipitation, BTK knockdown with GNA15-overexpression rescue, and viability/migration/invasion assays in thyroid carcinoma cells

   PMID:38333922

   Open questions at the time

   • Mechanism of Gα15–BTK binding (direct vs indirect) not resolved
   • Single lab, single tumor type
5. 2024 Medium

   Identified CD312 as a GPCR that engages Gα15 at its transmembrane intracellular segment to drive leukemia proliferation, extending the receptor repertoire feeding into Gα15-MAPK signaling.

   Evidence Transmembrane interaction binding assay, BrdU proliferation, GNA15 knockdown in a co-culture system with MAPK Western blots

   PMID:39656442

   Open questions at the time

   • Structural basis of the transmembrane interaction not defined
   • Co-culture system may not reflect cell-autonomous signaling
6. 2025 Medium

   Connected Gα15 to metabolic reprogramming, showing it activates AMPK-driven fatty acid oxidation to confer drug resistance—revealing a non-MAPK output relevant to therapy.

   Evidence Metabolomics, p-AMPK/CPT1/CPT2/CD36 Western blots, FAO inhibition with etomoxir, and overexpression/knockdown functional assays in B-ALL cells

   PMID:39812998

   Open questions at the time

   • How GPCR/Gα15 signaling links mechanistically to AMPK activation unresolved
   • FAO inhibition only partially reverses resistance, implying additional effectors
7. 2023 Low

   Placed GNA15 under miR-211-5p control as a node influencing pyroptosis, glycolysis, and tumor-microenvironment immune function in melanoma metastasis.

   Evidence miRNA target validation, gain/loss-of-function, glycolysis/pyroptosis assays, and exosome transfer in melanoma cell lines

   PMID:36642112

   Open questions at the time

   • GNA15-specific mechanism relies heavily on computational prediction with limited direct validation
   • Causal chain from GNA15 to pyroptosis/glycolysis not dissected

• It remains unknown how Gα15's promiscuous receptor coupling is mechanistically reconciled with both MAPK activation and AMPK-driven metabolic rewiring, and whether a single effector logic operates across hematopoietic and solid-tumor contexts.
• No structural or biochemical reconstitution of Gα15 effector selectivity
• Direct effector(s) bridging Gα15 to AMPK not identified
• In vivo physiological role beyond cancer models uncharacterized